Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising plans through debt or equity in the provided transcript. The management discusses ongoing and planned capex and investments, highlighting strategic, planned expansion without indicating a need for new fundraising. Capex guidance for FY26 is increasing beyond ₹2,000 crores, and spending is being carefully planned and spread across multiple units. Cash on books is ₹3,451 crores as of September 30, 2025, indicating strong liquidity. No comments or indications about raising funds via equity or debt were made during the call. The com

Any current/future capex/capital investment/strategic investment?

Divi's Laboratories is executing three major capex programs focused on new technologies, capacity expansion, and key strategic projects. Capex is strategically planned and spread across all three production units, not concentrated in one. Capex guidance for FY26 was initially ₹2,000 crores, with ₹1,550 crores spent in H1; FY26 capex expected to be higher than ₹2,000 crores. Further investments will be aligned with long-term contracts and regulatory approvals, expected to start contributing revenues in 1-2 years. Ongoing construction of production blocks in Unit 3 for key starting materials; ad

Future growth expectations in sales/revenue/volumes?

The company has a healthy project pipeline, with multiple projects at different milestones; outcomes expected in next 1-2 years. Revenue growth driven by a mix of generic and custom synthesis (CS) businesses; CS currently contributing a larger share (~55%). Continued volume stability in the generic business despite pricing pressures; no customer or capacity loss reported. New generics coming off patent are expected to add volume and revenue. Custom synthesis business growth supported by advancing projects, including peptides and late-life cycle management; three major capex programs un

Future growth expectations in earnings/operating earnings/profits/EPS?

Divi's Laboratories anticipates positive growth in the next 1-2 years driven by new product launches, especially generics coming off patents, and growth in contract synthesis (CS) business (Pages 9, 16). The three new dedicated custom synthesis projects expected to start from Q4 FY27 should contribute to near-term and medium-term growth (Page 10). While generic segment faces pricing pressure, volumes remain stable, supported by backward integration, with hopes that pricing erosion will stabilize in upcoming quarters (Pages 6, 13, 16). Earnings growth will be influenced by product mix between g

Current/ Expected Orderbook/ Pending Orders?

The company has a strong and healthy pipeline of projects currently in various phases, including equipment installation, qualification, and validation. Revenues from the announced projects are expected to begin entering the books within the next 1 to 2 years, subject to regulatory approvals. Divi’s has several ongoing customer projects and long-term contracts that guide their investments and production schedules. Specific order book figures or the total value of pending orders were not disclosed due to confidentiality agreements. Management emphasized the robustness of the pipeline and

IN US

Sale is live|00:00:00left today

Divis Laboratories LtdQ3 FY25Pharmaceuticals & Biotechnology

Divis Laboratories Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹6,768P/E: 70.3Market Cap: ₹1.8L CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The company has a healthy project pipeline, with multiple projects at different milestones; outcomes expected in next 1-2 years.
→Revenue growth driven by a mix of generic and custom synthesis (CS) businesses; CS currently contributing a larger share (~55%).
→Continued volume stability in the generic business despite pricing pressures; no customer or capacity loss reported.
→New generics coming off patent are expected to add volume and revenue.
→Custom synthesis business growth supported by advancing projects, including peptides and late-life cycle management; three major capex programs underway to expand capacity.
→Peptide segment showing strong momentum with investments scaling up alongside customer regulatory progress.
→Nutraceutical business is evolving as a key growth driver.
→Constant currency revenue growth for H1FY26 is around 10.79%; full-year growth expected in a similar range.
→Overall positive outlook for revenue growth in next 1-2 years, supported by strategic investments and new product launches.

Margin guidance

Category 3

→Divi's Laboratories anticipates positive growth in the next 1-2 years driven by new product launches, especially generics coming off patents, and growth in contract synthesis (CS) business (Pages 9, 16).
→The three new dedicated custom synthesis projects expected to start from Q4 FY27 should contribute to near-term and medium-term growth (Page 10).
→While generic segment faces pricing pressure, volumes remain stable, supported by backward integration, with hopes that pricing erosion will stabilize in upcoming quarters (Pages 6, 13, 16).
→Earnings growth will be influenced by product mix between generics (45%) and CS (55%), with CS showing relatively better margins, but overall margin upside is limited due to ongoing generic pricing pressure (Pages 9, 16).
→Capex investments are strategically planned to support capacity expansion aligned with long-term contracts, enabling sustainable growth (Pages 7, 8).
→Management is hopeful about positive earnings outcomes from late-stage projects and sustainable contracts (Pages 12, 16).

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or future fundraising plans through debt or equity in the provided transcript.
→The management discusses ongoing and planned capex and investments, highlighting strategic, planned expansion without indicating a need for new fundraising.
→Capex guidance for FY26 is increasing beyond ₹2,000 crores, and spending is being carefully planned and spread across multiple units.
→Cash on books is ₹3,451 crores as of September 30, 2025, indicating strong liquidity.
→No comments or indications about raising funds via equity or debt were made during the call.
→The company focuses on long-term investments supported by existing resources and partnerships, rather than external capital raising.

Order book

Yes

→The company has a strong and healthy pipeline of projects currently in various phases, including equipment installation, qualification, and validation.
→Revenues from the announced projects are expected to begin entering the books within the next 1 to 2 years, subject to regulatory approvals.
→Divi’s has several ongoing customer projects and long-term contracts that guide their investments and production schedules.
→Specific order book figures or the total value of pending orders were not disclosed due to confidentiality agreements.
→Management emphasized the robustness of the pipeline and their readiness to scale capacity as needed, supported by multiple production blocks and available land for future expansion.

Capex plans

Yes

→Divi's Laboratories is executing three major capex programs focused on new technologies, capacity expansion, and key strategic projects.
→Capex is strategically planned and spread across all three production units, not concentrated in one.
→Capex guidance for FY26 was initially ₹2,000 crores, with ₹1,550 crores spent in H1; FY26 capex expected to be higher than ₹2,000 crores.
→Further investments will be aligned with long-term contracts and regulatory approvals, expected to start contributing revenues in 1-2 years.
→Ongoing construction of production blocks in Unit 3 for key starting materials; additional blocks to be built as needed on available land.
→Investments are being made in peptide manufacturing capacities and advanced technologies like flow chemistry, biocatalysis, and green chemistry.
→Divi's sees a positive outlook for capex and growth in the next 1-2 years, aligned with their strategy to become a global leader in peptides and complex APIs.

How does Divis Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Divis Laboratories Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Divis Laboratories Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio